The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation
Introduction. Overactive bladder (OAB) remains one of the most difficult-to-treat conditions in neurourology. The number of patients seeking help for OAB symptoms does not decrease each year, while a pathogenetic treatment has not yet been developed. This motivates the search for new approaches.Obje...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of Russian Federation, Rostov State Medical University, State Budget Educational Institute of Higher Professional Education
2024-09-01
|
| Series: | Вестник урологии |
| Subjects: | |
| Online Access: | https://www.urovest.ru/jour/article/view/920 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839577578938040320 |
|---|---|
| author | G. V. Kovalev I. A. Labetov R. R. Shakirova D. D. Shkarupa |
| author_facet | G. V. Kovalev I. A. Labetov R. R. Shakirova D. D. Shkarupa |
| author_sort | G. V. Kovalev |
| collection | DOAJ |
| description | Introduction. Overactive bladder (OAB) remains one of the most difficult-to-treat conditions in neurourology. The number of patients seeking help for OAB symptoms does not decrease each year, while a pathogenetic treatment has not yet been developed. This motivates the search for new approaches.Objective. To assess the efficacy of the peptide regulator Vezusten for women with idiopathic OAB based on their health condition and urodynamic assessment of bacterial detrusor overactivity (DO).Materials & methods. A prospective cohort study included 20 patients diagnosed with OAB, which was confirmed by a comprehensive urodynamic study of DO. The patients visited the clinic three times a week. Each patient received ten intramuscular injections of the peptide regulator Vezusten. Within one month after the last injection, the women were given a monitoring voiding diary, a validated Continental Society OAB Symptom Questionnaire, the Overactive Bladder Questionnaire (OAB-q), and a follow-up urodynamic study (UDS).Results. We obtained statistically significant differences in the following indicators: the number of daily urinations according to the urination diary decreased from 14.0 [13.0; 16.3] to 11.0 [8.8; 12.0] (p < 0,001), patient’s episodes of urge incontinence began to be noted for the first time (p = 0.004). At the same time, the urodynamic maximum cystometric capacity (MCC) increased from 267 [158; 332] to 320 [267; 433] ml. Subjectively, participants noted an improvement in the scores of the OAB questionnaire (OAB-q) — the score decreased from 28 [22; 30] to 19 [14; 24] (p = 0.001), and the number of episodes of nocturia decreased from 4 to 2 (p < 0.001). No side effects from therapy were observed in any of the patients.Conclusion. This study demonstrated a statistically significant improvement in subjective symptoms of OAB in DO-women treated with the peptide regulator Vezusten, but further large placebo-controlled studies are required for confirmation. |
| format | Article |
| id | doaj-art-dee5bfc526a544f78ceb51b648fc9f96 |
| institution | Matheson Library |
| issn | 2308-6424 |
| language | Russian |
| publishDate | 2024-09-01 |
| publisher | Ministry of Health of Russian Federation, Rostov State Medical University, State Budget Educational Institute of Higher Professional Education |
| record_format | Article |
| series | Вестник урологии |
| spelling | doaj-art-dee5bfc526a544f78ceb51b648fc9f962025-08-04T12:51:17ZrusMinistry of Health of Russian Federation, Rostov State Medical University, State Budget Educational Institute of Higher Professional EducationВестник урологии2308-64242024-09-01124505610.21886/2308-6424-2024-12-4-50-56554The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluationG. V. Kovalev0I. A. Labetov1R. R. Shakirova2D. D. Shkarupa3Pirogov Clinic of Advanced Medical Technologies — Saint Petersburg State UniversityPirogov Clinic of Advanced Medical Technologies — Saint Petersburg State UniversityPirogov Clinic of Advanced Medical Technologies — Saint Petersburg State UniversityPirogov Clinic of Advanced Medical Technologies — Saint Petersburg State UniversityIntroduction. Overactive bladder (OAB) remains one of the most difficult-to-treat conditions in neurourology. The number of patients seeking help for OAB symptoms does not decrease each year, while a pathogenetic treatment has not yet been developed. This motivates the search for new approaches.Objective. To assess the efficacy of the peptide regulator Vezusten for women with idiopathic OAB based on their health condition and urodynamic assessment of bacterial detrusor overactivity (DO).Materials & methods. A prospective cohort study included 20 patients diagnosed with OAB, which was confirmed by a comprehensive urodynamic study of DO. The patients visited the clinic three times a week. Each patient received ten intramuscular injections of the peptide regulator Vezusten. Within one month after the last injection, the women were given a monitoring voiding diary, a validated Continental Society OAB Symptom Questionnaire, the Overactive Bladder Questionnaire (OAB-q), and a follow-up urodynamic study (UDS).Results. We obtained statistically significant differences in the following indicators: the number of daily urinations according to the urination diary decreased from 14.0 [13.0; 16.3] to 11.0 [8.8; 12.0] (p < 0,001), patient’s episodes of urge incontinence began to be noted for the first time (p = 0.004). At the same time, the urodynamic maximum cystometric capacity (MCC) increased from 267 [158; 332] to 320 [267; 433] ml. Subjectively, participants noted an improvement in the scores of the OAB questionnaire (OAB-q) — the score decreased from 28 [22; 30] to 19 [14; 24] (p = 0.001), and the number of episodes of nocturia decreased from 4 to 2 (p < 0.001). No side effects from therapy were observed in any of the patients.Conclusion. This study demonstrated a statistically significant improvement in subjective symptoms of OAB in DO-women treated with the peptide regulator Vezusten, but further large placebo-controlled studies are required for confirmation.https://www.urovest.ru/jour/article/view/920overactive bladderdetrusor overactivitycomplex urodynamic studypeptide regulator |
| spellingShingle | G. V. Kovalev I. A. Labetov R. R. Shakirova D. D. Shkarupa The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation Вестник урологии overactive bladder detrusor overactivity complex urodynamic study peptide regulator |
| title | The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation |
| title_full | The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation |
| title_fullStr | The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation |
| title_full_unstemmed | The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation |
| title_short | The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation |
| title_sort | peptide regulator vezusten in the management of overactive bladder syndrome an efficacy evaluation |
| topic | overactive bladder detrusor overactivity complex urodynamic study peptide regulator |
| url | https://www.urovest.ru/jour/article/view/920 |
| work_keys_str_mv | AT gvkovalev thepeptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation AT ialabetov thepeptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation AT rrshakirova thepeptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation AT ddshkarupa thepeptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation AT gvkovalev peptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation AT ialabetov peptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation AT rrshakirova peptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation AT ddshkarupa peptideregulatorvezusteninthemanagementofoveractivebladdersyndromeanefficacyevaluation |